Hello, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? After all, consider the alternatives. Meanwhile, there is much to be done — meetings, deadlines, phone calls, bracing for the future. So please join us as we grab a cup of stimulation and dig in for another busy day. If you need a break, by the way, you can vote for the best biopharma CEO of the year (a separate list will appear shortly for the worst CEO, so sit tight). Meanwhile, here are some tidbits to help you get going. Have a splendid day and, of course, do keep in touch …

The House approved a proposal cracking down on the tactics drug makers use to charge Medicaid, The Hill writes. The bipartisan bill comes after the Department of Health and Human Services last year accused Mylan (MYL), which sells EpiPen, of overcharging Medicaid by as much as $1.27 billion over 10 years by misclassifying the drug as a generic. The bill would give HHS new authority to reclassify a drug and recoup rebates when a manufacturer deliberately misclassifies a drug in order to pay lower rebates.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy